Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Two out of three people under the age of 40 are at risk of prediabetes
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
